Printer Friendly

ZymoGenetics obtains United States patent.

ZymoGenetics, Inc. (Seattle, WA) has patented isolated DNA molecules comprising a DNA segment encoding a glucagon receptor. Also provided are DNA constructs comprising a first DNA segment encoding a glucagon receptor operably linked to additional DNA segments required for the expression of the first DNA segment, as well as host cells containing such DNA constructs. The present invention also provides a method for detecting the presence of glucagon antagonists, comprising the steps of (a) exposing a compound in the presence of a glucagon against to a recombinant glucagon receptor coupled to a response pathway under conditions and for time sufficient to allow binding of the compound to the receptor and an associated response through the pathway, and (b) detecting a reduction in the stimulation of the response pathway resulting from the binding of the compound to the glucagon receptor, relative to the stimulation of the response pathway by the glucagon agonist alone and therefrom determining the presence of a glucagon antagonist. (US 5919635)
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Jan 1, 2000
Previous Article:Asahi obtains United States patent.
Next Article:Oregon Health Sciences University obtains United States patent.

Related Articles
Pharming announces patent proceeding against PPL Therapeutics.
ZymoGenetics files patent infringement suit against.
ZymoGenetics and Arriva sign recombinant alpha 1-antitrypsin agreement.
ZymoGenetics licenses interleukin-13 receptor subunit.
ZymoGenetics establishes global collaboration with Bayer for development and commercialization of recombinant human thrombin.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters